The Medical Cannabis Bill Advances in Brazil

A few days ago, the Speaker of the Chamber of Deputies and the Minister of Agrarian Development met to discuss the initiative that seeks to regulate the production and marketing of medical cannabis derivatives.

Currently, more than 430,000 Brazilians use medical cannabis

They access these products by purchasing them in pharmacies or through the 200 civil associations currently authorized by the court to prepare preparations for their members. The entire cannabis-related market generated a total of 700 million reais (112 million euros) last year, according to a study conducted by the consulting firm Kaya Mind. However, this occurs in a context in which the country still lacks specific regulations on medical cannabis.

The situation, however, could soon be changing. A few days ago, the Speaker of the Chamber of Deputies, Hugo Motta, and the Minister of Agrarian Development and Family Farming, Paulo Teixeira, met to discuss a parliamentary initiative seeking to legalize the production and sale of medical cannabis for therapeutic purposes.

“The production of phytotherapeutic medicines by family farmers is one of our department’s priorities,” stated Minister Teixeira after the meeting with the parliamentary leader, during which they discussed Bill 399/2015, which proposes regulating the production and sale of Cannabis sativa- based medicines. Furthermore, Teixeira emphasized the urgency of submitting the medical cannabis bill initiative to a plenary vote and reaffirmed the strategic role played by patient and producer associations in advancing this agenda in Brazil.

There is still no agreement among the country’s various political parties to debate the medical cannabis bill in parliament. However, before that happens, the Chamber of Deputies is expected to convene representatives of various cannabis-related civil associations to strengthen the legislative text.

__

(Featured image by Shelby Ireland via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in CANAMO. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us